Objective-Cocaine consumption is a risk factor for vascular ischemic complications. Although endothelial dysfunction and accelerated atherosclerosis have been observed in cocaine consumers, the mechanisms underlying their pathogenesis are not fully understood. This study aimed at identifying the effects of atorvastatin in relation to a proadhesive and prothrombotic phenotype induced by cocaine and plasma from chronic cocaine users on endothelial cells. Approach and Results-Human umbilical vein endothelial cells were exposed to either cocaine or platelet-free plasma (PFP) from chronic cocaine consumers in the presence or absence of 10 μmol/L of atorvastatin. Atorvastatin significantly reduced the enhanced platelet adhesion that was induced by cocaine and PFP from chronic cocaine consumers, as well as the release of the von Willebrand factor. Atorvastatin also avoided striking alterations on cell monolayer structure triggered by both stimuli and enhanced NO reduction because of cocaine stimulation through disrupting interactions between endothelial nitric oxide synthase (eNOS) and caveolin-1, thus increasing eNOS bioavailability. Cocaineincreased tissue factor-dependent procoagulant activity and reactive oxygen species generation were not counteracted by atorvastatin. Although monocyte chemoattractant protein-1 levels were not significantly higher than controls either under cocaine or PFP stimulation, atorvastatin completely avoided monocyte chemoattractant protein-1 release in both conditions. Platelets stimulated with cocaine or PFP did not express P-selectin, glycoprotein IIb/IIIa, or CD40L and failed to adhere to resting human umbilical vein endothelial cell. 
C ocaine consumption, which is considered to be one of the most prevalent addictions worldwide, is associated with accelerated atherosclerosis, greater risks of cardiovascular disease, and fatal ischemic events. 1 The mechanisms underlying the deleterious vascular effect of cocaine use involve vasoconstriction-vasospasm, endothelial dysfunction, and thrombogenesis. 2, 3 The pathogenesis of cocaine-induced arterial obstruction is probably multifactorial although evidence provided by studies using experimental animal models 4, 5 and observations in cocaine abusers suggests that hemostatic system activation may play an important role, being that it promotes thrombus formation. 6 Findings from the available literature 7 and our own data 8 strongly support the notion that endothelial cell (EC) damage is a major phenomenon observed in chronic cocaine consumers. Evidence of endothelial dysfunction in cocaine users has been observed in different model systems. In an ex vivo study, for instance, we identified several significantly elevated endothelial dysfunction markers in chronic cocaine users, especially circulating ECs. After the patients underwent a short period of cocaine withdrawal, some markers diminished to normal values, but circulating ECs and monocyte chemoattractant protein-1 (MCP-1) levels remained elevated. 8 The latter suggests that EC impairment induced by cocaine consumption persists even beyond the acute effect of the drug.
In vitro studies using human aortic ECs showed that cocaine induced a significant increase in tissue factor (TF) expression and reduced TF pathway inhibitor levels after thrombin stimulation when compared with cells that were stimulated with thrombin in the absence of cocaine. 9 Also in human aortic ECs, a decrease in nitric oxide (NO) production, as well as an elevated expression of endothelin-1 and higher leukocyte adhesion, was observed on cocaine stimulation for 24 hours. 7 In bovine coronary artery ECs, He et al 10 further demonstrated that decreases in endothelial nitric oxide synthase levels (eNOS) reduce intracellular calcium mobilization and alter eNOS, subcellular localization. These effects were associated to decreases in NO induced by cocaine.
In addition to NO imbalance, the endothelium expresses platelet-binding and stimulating agents, such as multimeric von Willebrand factor (VWF), TF, and adhesion molecules. 11, 12 The interaction of platelets with endothelial results in proinflammatory signals, the release of chemokines, and the upregulation of receptors mediating downstream events, thus highlighting the key role of platelets in atherosclerosis development and progression. 12, 13 Platelet activation has also been implicated as a possible mechanism by which cocaine promotes thrombus formation. 14, 15 Chronic cocaine consumption is associated with elevations of CD40L, neutrophil-activating protein-2 (CXCL7), and Regulated on Activation, Normal T Cell Expressed and Secreted levels in the plasma. The continuous presence of cocaine in circulation (as seen in chronic cocaine abusers) would provide an environment of constant stimulation for platelets, supporting their contribution to the development of ischemic-vascular complications associated with cocaine consumption.
Although endothelia and platelets have been studied separately in relation to the pathogenesis of atherothrombotic complications in cocaine addicts, there is limited information from models involving the interaction between platelets and ECs in relation to cocaine. Recently, Hobbs et al 16 reported increased multimeric VWF secretion from brain microvascular, coronary artery, and human umbilical vein ECs (HUVEC) induced by cocaine and metabolites. In addition, they observed glycoprotein Ibα-dependent platelet binding to VWF strings that remained on the surface of EC treated with cocaine.
The persistent interaction between platelets and ECs seemed to be a key phenomenon at the onset of the atherogenic process 17 and, regardless of which contributor may have the pivotal role, improving endothelial function would be the most direct way to delay the progress of the vascular disease. Statins, well known for their lipid-lowering properties, have also shown to improve endothelial dysfunction, by influencing platelet activation and inflammation. [18] [19] [20] The clinical pleiotropic effects of atorvastatin have been demonstrated to improve endothelial function by increasing NO bioavailability after 3 days of administration effectively. This is achieved without affecting low-density lipoprotein-cholesterol or cholesterol levels in patients with cardiovascular risk or established coronary artery disease. 21 In the endothelium, atorvastatin downregulates endothelin-1, 22 CD40, 23 and vascular cell adhesion molecule-1 24 expression, and increases NO as well as eNOS levels. 25 In patients with coronary artery disease, atorvastatin reduces CD40L expression and improves activation markers in platelets. 26 The main objective of this work was to evaluate whether atorvastatin can modify the enhanced adhesive and procoagulant phenotype induced by cocaine in human ECs. Our finding showed that activation markers derived from blood cells persist even after short-term abstinence 8 suggests that the endothelium of chronic cocaine consumers might be exposed to a variety of bioactive mediators besides cocaine or its metabolites. On the basis of this finding, we also examined whether platelet-free plasma (PFP) from chronic cocaine consumers can induce alterations in ECs similar to those provoked by cocaine.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
As previously mentioned, adhesion of platelets to an activated endothelium is a fundamental step during atherogenesis. Statins, however, improve several EC functions, 19 including the secretion of VWF from EC stimulated with thrombin. 27 Here, we report on the effect of atorvastatin on VWF release and platelet adhesion to HUVEC on exposure to cocaine and plasma from chronic cocaine consumers.
Atorvastatin Reduced Enhanced Platelet Adhesion to HUVEC Induced by Cocaine and Moderately Decreased the Exposure of VWF on Cell Surface
HUVECs exposed to cocaine either in the presence or in the absence of atorvastatin were coincubated with resting platelets and evaluated by immunostaining for VE-cadherin or VWF for ECs and glycoprotein Ibα for platelets. As observed in Figure 1A , the number of platelets adhered to EC increased dramatically after 5 hours of cocaine exposure when compared with HUVEC stimulated with the vehicle (220±73.54 versus 10 tested for signs of apoptosis with propidium iodide or caspase 3 cleavage products, which showed no differences from control cultures (data not shown). The quantification of platelets adhered to HUVEC is shown in Figure 1B . The number of platelets adhered to cocaine-treated HUVEC was ≈200-fold higher than vehicle-treated cells and atorvastatin reduced the number of adhered platelets to <10 platelets per 100 ECs. Figure 1C shows that cocaine induced the expression of significant amounts of VWF on HUVEC surfaces when compared with control cells. Although atorvastatin significantly reduced cocaine-induced platelet adhesion, it only moderately diminished VWF expression. Under our experimental conditions, cocaine failed to increase VWF release to the supernatant, even in cells treated for 24 hours with cocaine (data not shown). A higher concentration of cocaine (100 μmol/L) or cotreatment with atorvastatin did not modify the amount of VWF released by untreated cells ( Figure 1D ). Furthermore, treatment only with PFP-CP induced changes in cell shape toward a fibroblast-like phenotype, which was completely restored to normal by atorvastatin ( Figure 2A ). Just like cocaine, PFP-CP supplementation significantly increased VWF expressed on the cell surface. The latter was significantly reduced by atorvastatin to levels comparable with HUVEC supplemented with PFP-NP ( Figure 2C ).
Increased Platelet
Unlike observations in cocaine-treated cells, increased levels of secreted VWF were found in the supernatants of HUVEC supplemented with PFP-CP when compared with those treated with PFP-NP (188±76.43 versus 77.06±25.61 UI/dL, respectively; P=0.0403; Figure 2D ). To discard the differential contribution of ADAMTS13 coming from the plasmas used for supplementation, we determined the activity of this protease in patients and controls. As shown in Figure I in the online-only Data Supplement, there were no significant differences in ADAMTS13 activity between chronic cocaine consumers and their respective control subjects (107.7±7.218 versus 102.1±6.997% of normal pooled plasmas). Although atorvastatin significantly reduced VWF on cell surfaces, it only partially diminished its release to the supernatant from cells stimulated with PFP-CP for 5 hours (104.8±51.67% UI/dL), as shown in Figure 2D . However, in HUVEC incubated for 24 hours, atorvastatin significantly reduced VWF secretion when compared with PFP-CP (77.09±33.08 versus 256.0±59.07% UI/dL respectively; P=0.036; not shown).
Platelets Stimulated With Either Cocaine or PFP-CP Did Not Adhere to Healthy HUVEC
Chronic cocaine consumers showed elevated levels of several platelet activation markers as reported by our group. 14 Thus, we investigated whether cocaine or patient PFP would activate platelets, which could lead to increased adhesion to untreated ECs.
As shown in Figure 3A and 3B, neither cocaine nor plasma stimulation increased P-selectin exposure in platelets, as assessed by flow cytometry. No significant differences were observed between untreated or treated platelets even with a higher concentration of cocaine. Moreover, atorvastatin did not affect P-selectin exposure in platelets. Platelets stimulated with thrombin receptor activating peptide exposed large amounts of P-selectin (42.0±5.04%), denoting platelet activation capability under assay conditions ( Figure 3B ). In addition, stimulated platelets did not exhibit CD-40 L or activation of glycoprotein IIb/IIIa because they did when activated by thrombin (data not shown). Despite these results, platelets incubated with cocaine exhibited reduced NO content when compared with untreated cells (0.158±0.01 versus 0.195±0.03 arbitrary fluorescence units (AFU), respectively; P=0.0156), as well as with PFP-CP when compared with PFP-NP (0.263±0.015 versus 0.331±0.016 AFU, respectively; P=0.005; Figure 3C and 3D). Atorvastatin, completely avoided decreases in NO in platelets stimulated by cocaine (0.181±0.02 versus 0.158±0.01 AFU, respectively; P=0.0313; Figure 3C ). Adhesion of platelets stimulated with cocaine or PFP to untreated HUVEC showed <10 platelets per 100 HUVECs adhered under all experimental conditions, as observed in Figure 3E . 
Atorvastatin Counteracts MCP-1 Levels Released by HUVEC Stimulated With Cocaine or With PFP From Chronic Cocaine Consumers
MCP-1 participates in the development of atherosclerotic lesions by promoting the recruitment of monocytes at vascular inflammation sites. 28 In HUVEC, MCP-1 is synthesized and released by inflammatory cytokines and platelet adhesion. 29 Statins were reported to reduce MCP-1 levels in vivo and in several in vitro models. 30, 31 As observed in Figure 4A and 4B, exposure of HUVECs to cocaine or PFP-CP resulted in a slight (not significant) increase in levels of released MCP-1.
Nevertheless, atorvastatin significantly reduced, such MCP-1 levels from 128.2±20.87 to 93±7.23% (P=0.031) in cocainetreated cells and from 149±51.03% to 107±34.95% (P=0.039) in PFP-CP-treated cells ( Figure 4B ).
Cocaine and PFP From Chronic Cocaine Users Increased TF-Dependent Procoagulant Activity
The loss of antithrombotic properties and increased procoagulant activity (PCA) by damaged/activated endothelia is another characteristic feature of endothelial dysfunction. 32, 33 Because thrombin generation is a key phenomenon in the pathogenesis of vascular ischemic complications, we assessed TF-PCA in HUVEC stimulated by cocaine or PFP-CP. Figure 5A shows that cocaine induced a significant increase in TF-PCA when compared with untreated cells (150.8±27.7% versus 100% of control; P=0.0238). However, as shown in Figure 5B , the increased PCA of cells stimulated with PFP-CP did not reach significance with respect to cells incubated with PFP-NP (224.2±92.88% versus 100%, respectively), which is probably because of the variability of the data. Atorvastatin neither prevent PCA increases induced by cocaine (119±28.95 versus 150.8±27.7%, respectively; P=0.156) nor affect the PCA of cells treated with PFP-CP (178.2±62.57%, respectively; P=0.219) as observed in Figure 5A and 5B.
Atorvastatin Avoided the Reduction of NO Induced by Cocaine or by Plasma From Chronic Cocaine Consumers, but Did Not Modify Reactive Oxygen Species Generation
Considering that one of the best known pleiotropic effects of statins is to improve NO bioavailability, we studied whether atorvastatin can modify NO and reactive oxygen species (ROS) in HUVEC stimulated with PFP-CP. In agreement with reports based on other experimental models, 7, 10 NO significantly decreased in HUVEC stimulated with cocaine when compared with untreated cells (0.297±0.013 versus 0.583±0.133 AFU, respectively; P=0.0225). Atorvastatin completely re-established the NO content to levels similar to those found in untreated cells (0.523±0.083 versus 0.583±0.133 AFU, respectively; P=0.0313; Figure 6A ). Cells coincubated with atorvastatin and cocaine for 5 hours showed a tendency to increase eNOS levels without affecting their phosphorylation states ( Figures IIA-IIC Figure 6C ).
HUVEC treated for 5 hours with cocaine generated significantly more ROS than untreated cells (8.011±0.323 versus 2.753±0.919 AFU, respectively; P=0.0014) as observed in Figure 6B . Although HUVEC stimulated with PFP-CP showed a tendency to generate more ROS, they did not reach significant levels (17.77±10.59 versus 6.617±2.401 AFU, respectively; P=0.109; Figure 6D ).Unexpectedly, atorvastatin did not change ROS generation levels either in cocaine-stimulated cells or in PFP-CP-supplemented cells ( Figure 6E ).
Discussion
Cocaine is one of the most frequently used illicit drugs associated with severe cardiovascular events. The mechanisms involved in the deleterious effects of cocaine on the vasculature are undoubtedly multifactorial, yet the loss of the endothelium's protective functions seems to be a common denominator. In this regard, actions taken toward improving endothelial dysfunction could have an effect on the management of cardiovascular complications related to drug addiction. Here, we confirmed the protective action of atorvastatin by inhibiting proadhesive and prothrombotic changes in ECs induced by cocaine or by plasma from chronic cocaine consumers.
We observed that ECs exposed to cocaine displayed a notable proadhesive phenotype, enhancing significantly the binding of platelets under static conditions. The most remarkable observation of this study was the complete inhibition of platelet adhesion to cocaine-treated ECs by atorvastatin. Similarly, when HUVECs were incubated with PFP-CP, the binding of platelets was enhanced and then significantly reduced by atorvastatin. Under both experimental conditions, the increase in binding of platelets was associated with enhanced VWF deposited on the surfaces of ECs. However, atorvastatin was more effective in reducing VWF of cells stimulated with PFP-CP than those stimulated with cocaine. The results observed from cocaine stimulation were in agreement with those reported by Hobbs et al. 16 in different tissue-derived EC lines stimulated with cocaine and several metabolites. The authors showed that cocaine induces the release of VWF under flow, thus forming strings on the cell surface to which platelets adhere. In our study, we used atorvastatin to inhibit the adhesion of platelets to HUVEC stimulated with cocaine and observed the same response when HUVEC were exposed to PFP-CP from chronic cocaine consumers. The effect of plasma was exclusive of PFP-CP because PFP from noncocaine consumers did not induce either VWF release or platelet adherence. Our previous report showed that chronic cocaine users have elevated levels of several platelet 14 and EC 8 activation markers that remain in circulation beyond the half-life of cocaine metabolites. On the basis of the latter observation, our results on PFP stimulation and atorvastatin inhibition are of particular interest because these conditions may replicate the environment to which vascular endothelia of the addicted patients is exposed. Although atorvastatin was observed to reduce both significantly, platelet adhesion and VWF expression on the cell surfaces of HUVEC treated with PFP-CP, it only moderately diminished VWF in the case of cells stimulated with cocaine although it significantly reduced the number of platelets adhered. Patients and the control group did not show any differences in ADAMTS13 activities. As a result, the enzyme activity in plasma did not account for the higher VWF found in cell supernatants of HUVEC stimulated with PFP-CP. Additional studies are required to disclose the presence of other proteases in PFP-CP (but not in PFP-NP) that could cleave VWF 34 and other factors within PFP-CP that would induce higher ADAMTS13 released by ECs.
Platelets express many ligands and receptors that, on activation, enable interactions between them, as well as with leukocytes and ECs. In addition to membrane glycoproteins and P-selectin, platelets express various integrins that can also interact with molecules lying on ECs, such as intercellular adhesion molecule. 35 We showed that platelets from chronic cocaine patients after recent consumption seem activated, as reflected by elevated levels of platelet activation markers in circulation.
14 Hence, we evaluated whether activation of platelets with a similar approach to that of HUVEC stimulation would be sufficient to promote increased adhesion to nonstimulated ECs. Cocaine and PFP induced a significant decrease in platelet NO content, which did not result in increased adhesion to nonstimulated HUVECs. Independent of the stimulation conditions, neither cocaine nor PFP, induced the expression of P-selectin or CD40-L or the activation of glycoprotein IIb/ IIIa. These results suggest that under our experimental conditions, endothelial activation is required for providing the adequate environment for platelet adhesion rather than solely platelet activation.
Statins have been reported to downregulate MCP-1 levels in several experimental settings and animal models effectively. 30, 36 MCP-1 is one of the cytokines greatly implicated in the progress of atherosclerosis, mainly because of its ability to attract monocytes to the damaged sites of the endothelium. In relation to cocaine, MCP-1 has been studied in association to HIV 37, 38 and in chronic cocaine consumers by our group. 8 However, atorvastatin intervention in experimental models, in which MCP-1 is investigated in relation to cocaine, has not been reported. Here, we showed that although 5 hours of cocaine or PFP-CP exposure only tended to elevate MCP-1 levels, atorvastatin completely held back MCP-1 production to values comparable with controls. Activated platelets have also been reported as contributors to an increased release in endothelial MCP-1. 29 Although not evaluated here, we might speculate that the release of endothelial MCP-1 caused by cocaine stimulation would be enhanced by the increased adhesion of platelets under cocaine or PFP stimulation. The effect of atorvastatin should be re-evaluated under this experimental setting. Increased TF expression along with a reduced TF pathway inhibitor has been reported in response to cocaine. 9 Nevertheless, whether this has consequences on TF-dependent PCA had not been studied until now. We found that only cocaine induced a significant increase in TF PCA in HUVEC, which unexpectedly was not abolished by atorvastatin under our experimental conditions. Although there are no data specifically on the effect of atorvastatin on TF-dependent PCA associated with cocaine, it has been shown that statins reduce monocyte TF levels and activity in other experimental settings. 39 Additional investigations are needed to clarify the lack of atorvastatin effectiveness in lowering TF PCA induced by cocaine.
One of the best known pleiotropic effects of statins is that of increasing NO production. 22 In HUVEC, both cocaine and PFP-CP similarly decreased NO content by ≈57% when compared with untreated or PFP-NP-supplemented cells. In addition, as expected, atorvastatin effectively impeded this reduction. Although eNOS levels and bioavailability have been reported to be involved in the mechanisms by which cocaine diminishes NO release in bovine coronary artery ECs, 10 the mechanism through which atorvastatin impedes NO reduction is still unknown. Our results showed that atorvastatin impeded the reduction of eNOS induced by cocaine to some extent and reduced caveolin-1 protein levels even to lower level than control cells. These results agreed with reports showing that atorvastatin decreases caveolin-1 expression in bovine ECs treated with low-density lipoproteincholesterol. The effect of atorvastatin was shown to be independent from extracellular low-density lipoprotein-cholesterol. 40 In addition, atorvastatin strongly modified eNOS subcellular localization by visibly diminishing its association to caveolin-1. Although the dispersed distribution of eNOS in control cells and the changes observed on cocaine stimulation are in agreement with results reported for bovine aortic ECs by He et al, 10 the association between eNOS and caveolin-1, as well as the dramatic effect of atorvastatin on cocaine-treated ECs, has not been evidenced before.
These results showed that the addition of atorvastatin to cocaine-treated cells for 5 hours triggers cell dynamic changes PMA 1µM
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PFP-NP PFP-CP Atorvastatin 10 µM that result in a disruption of the interactions between eNOS and caveolin-1 at the cell membrane, most probably causing increased eNOS bioavailability. It may be possible that atorvastatin would target rapid mechanisms involved in protein mobilization at the subcellular level, which might be reflected in changes of active eNOS at later times of culture. In other cell systems, eNOS is also regulated by its membrane location-sequestration into caveolae, specifically by its interaction with caveolin-1 (among others). 41 The effect of atorvastatin on caveolin-1 could account, at least in part, for the mechanism involved in the prevention of NO reduction induced by cocaine. In human aortic ECs, cocaine has been reported to decrease NO production along with increasing the expression of endothelin-1 (as well as its receptor) and enhancing monocyte adhesion. The specific inhibition of the endothelin-1 receptor has been observed to amend the reduction of NO and monocyte adhesion partially, suggesting a possible mechanism by which cocaine induces endothelial damage. 7 Whether the effect of atorvastatin involves endothelin-1 or its receptor remains to be studied.
Cocaine, not PFP-CP, significantly induced ROS production after 5-hour stimulation, which was a phenomenon that was not affected by atorvastatin. It has been reported that pretreatment of human aortic ECs with atorvastatin reduces ROS liberation induced by tumor necrosis factor-α. 42 However, in our experimental model, cotreatment with atorvastatin did not show the same results and possibly denoting differences in experimental designs.
A remarkable observation was the effect of atorvastatin in recovering cell monolayer structure, which was altered by cocaine and PFP -CP stimulation. The consequences comprised in cytoarchitecture changes induced by cocaine and PFP and the capacity of atorvastatin to prevent these alterations completely warrant further studies aiming to identify the specific pathways involved in this phenomenon.
In summary, our results showed that ECs exposed to cocaine and to PFP from cocaine consumers exhibit comparable changes, resulting in a prothrombotic phenotype. Atorvastatin improved most of the damages induced by both stimuli, except for PCA and ROS generation. Although several preventive effects of atorvastatin may occur in response to increase NO bioavailability, the exact signaling pathways involved in cocaine-related stimulation of ECs are still under investigation.
